Podcasts about Reduction

How can we enjoy dining out without derailing our nutrition? We're talking about 1,000 calorie salads(!), why restaurants aren't incentivized to offer healthy options, some of my favorite go-to spots, and more. Learn more about the Nutrition for the 99% Seminars here! --- Referenced Episodes: On Weight, Health, and Worth Referenced Studies: Liu et al., 2020. Health and economic impacts from menu labeling. Rozin et al., 2003. French paradox. Shangguan et al., 2019. Reduction in calories from menu labeling. --- Subscribe for more on Apple or Spotify. Leave us a Voice Message. Find us on Social: EC | Patrick --- OptimizeMe Nutrition Products 30 Days of the #800gChallenge® program 30 Days of Lazy Macros™ program Masterclass program (8 Week program with live coaching options in Jan, April, and Sept) Gym Nutrition Challenges Corporate Wellness About the Show The Consistency Project aims to simplify nutrition, health, and well-being by breaking down the concepts and actions we can all take to live fuller, more functional lives. Become a paid subscriber on Apple Podcasts and Spotify to access more! About EC EC Synkowski is a Certified Nutrition Specialist® (CNS), a Licensed-Dietitian Nutritionist (LDN), and Certified CrossFit Level 4 Coach (CF-L4). She's the founder of OptimizeMe Nutrition and the creator of the #800gChallenge®. About Patrick The Consistency Project is produced and co-hosted by Patrick Cummings, a long-time CrossFitter, podcaster, and brand coach to gym owners & entrepreneurs. Disclaimer: The information is being provided to you for educational and informational purposes only. It is to educate you about general nutrition practices and as a self-help tool for your own use. It is not meant to substitute for the advice provided by a medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. This information is to be used at your own risk based on your own judgment. Click for full disclaimer. --- Send in a voice message: https://anchor.fm/theconsistencyproject/message

Sylvain Pataille is the owner and winemaker at Domaine Sylvain Pataille, which is located in the Marsannay area of Burgundy, within France.Sylvain discusses the impact in Burgundy of economic changes over the last one hundred years, and notes the special situation of Marsannay, which is near the city of Dijon in France. He does into some depth about the the vine planting history of the Marsannay area, and the commercial success of rosé wine from Marsannay. Sylvain then relates the more recent history of his own family's wine domaine, including its association with the Aligoté grape. This leads him to contrast old viticultural practices in the region, which he has identified from reading older books, with more recent norms.Sylvain also describes his own progression in oenology, from a more technical lab background to his very different focus today. He talks about working with "the best and worst" winemakers in Burgundy as an oenological consultant, and what feelings led him to leave that sort of business behind, with a shift of focus to his own wine domaine. This episode also features commentary from:Bruno Clair (translated by Peter Wasserman), Domaine Bruno ClairJohn Kongsgaard, Kongsgaard WineBecky Wasserman, Becky Wasserman & Co.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Not everyone enjoys talking about taxes, but with the current state of the economy, you need to locate the best accountant to meet your demands. In today's episode, Catherine Tindall discusses the tax planning and techniques you'll need to help you upgrade your portfolio. Key Takeaways To Listen ForHow tax depreciation impacts investorsDifferences between active and passive investment tax benefitsHow to choose and evaluate the right accountant for your investmentsWhat to keep an eye out for changing tax landscapeWays to utilize 1031 exchangeTips to efficiently work with your accountantAbout Catherine TindallCatherine Tindall is a CPA, and partner at Dominion Enterprise Services, a concierge tax advisory practice. With all the recent and upcoming tax changes, I am excited to talk to an expert that can help us, not only stay informed but also provide some insight into how we can reduce our overall tax burden. Connect with CatherineWebsite: Dominion Enterprise ServicesLinkedIn: Catherine Tindall, CPATo Connect With UsPlease visit our website: www.bonavestcapital.com and please click here, to leave a rating and review!SponsorThinking About Creating and Growing Your Own Podcast But Not Sure Where To Start?Visit GrowYourShow.com and Schedule a call with Adam A. Adams

Wesley Sierk is the President and Lead Strategist at Risk Management Advisors, Inc. and an expert in the implementation, design and management of captive insurance. With almost 20 years of experience in the field, Sierk has unique insights into the world of captive insurance, asset protection and risk management. Today, his firm manages the second-largest number of captives in the world. Wesley is a versatile, opinionated and dynamic speaker on a range of matters related to finance, business and insurance. He is also the author of two major books on the topics of asset protection and captive insurance, as well as a prominent keynote speaker at conferences around the United States. *DISCLAIMER - We are not giving any financial advice. Please DYOR* (00:00 - 1:50) Opening Segment -Introduction of the host into the show -Alpesh introduces the guest of the show, Wesley Sierks -Bob shares something interesting about himself (1:50 - 31:42) How To Use Captive Insurance For Asset Protection and Tax Reduction -Which assets doe's Sierks want to invest, and why? -Alpesh asks some questions -Is there any tool or website Wesley recommends -Wesley gives advice to beginner investors (31:42 - 40:00) Fire Round -Would Wesley be changing business strategy after the pandemic -Wesley shared a book he read (40:00 - 41:25) Closing Segment -If you want to learn more about the discussion, you can watch the podcast on Wealth Matter's YouTube channel and you can reach out to Alpesh using this link. Facebook: @wealthmatrs IG: @wealthmatrs.ig Tiktok: @wealthmatrs

Check out the https://my.captivate.fm/chemistrymadesimple.net/program (Chemistry Made Simple academy) In this episode: definition of the terms oxidation and reduction simple examples of oxidation and reduction definition of oxidation states / oxidation numbers with examples definition of redox Find out more about the https://my.captivate.fm/chemistrymadesimple.net/program (Chemistry Made Simple academy)  Contact me: Instagram https://www.instagram.com/chemistrymadesimple (@chemistrymadesimple) Email Matthew@ChemistryMadeSimple.net Join the discussion at the https://www.facebook.com/groups/chemistrypodcastcommunity (Chemistry Made Simple podcast community).

00:00 What PPC rank should you be going for00:44 Showcase how you can look at your organic rank or PPC rank02:35 How to track Keywords03:21 Typically, it's slot 3 & 405:10 I'm already in the organic position 1-4, should I still be doing PPC08:24 You can do a nice video Ad placementJoin our Channel to get early access and say thanks to Steven Pope for putting out all the content: https://www.youtube.com/channel/UClUSEsDS2sdgNJfCcCM_5Uw/joinAbout Steven Pope: Steven is the founder of My Amazon Guy. He started his career as a TV reporter in Idaho, then was an eCommerce Director for 10 years for brands ranging from Gold & Silver Coins to Women's Plus Size Clothing. Steven created My Amazon Guy because of how difficult it has become to grow sales on Amazon. Steven owns MAG, My Refund Guy - a clawback FBA service, and Momstir - a Private Label FBA Wine Glass brand with the #1 funny wine glass on Amazon. He has more than 600 tutorial videos on YouTube showing how to handle ANY problem faced on Amazon. Steven also hosts a podcast with interviews from other Amazon experts. LinkedIn // Degrees: MBA and BS In Communications. Amazon Advertising Sponsored Ads Accredited.About My Amazon Guy: An 160+ client full-service Amazon Agency in Atlanta, Georgia. We growth hack sales through traffic and conversion improvements. PPC, SEO, Design, Catalog Merchandising, and more all in-house. My Amazon Guy Podcast and Videos: Podcast.MyAmazonGuy.comYouTube.com/MyAmazonGuyWebsite: MyAmazonGuy.comOther Social Media links:https://www.facebook.com/myamazonguys/https://www.linkedin.com/company/my-amazon-guyhttps://twitter.com/myamazonguy✅Get 50% off First Month with Helium 10 https://bit.ly/3z1sijm✅ Order a Trademark from My Amazon Guy for $825 and get your brand registry on Amazon in under 7 days. Order here: https://myamazonguy.com/trademark-services/✅ A+ Enhanced Brand Content https://myamazonguy.com/amazon-enhanced-brand-a-plus-content/✅ Beginner Tutorial Playlist: https://www.youtube.com/playlist?list=PLDkvNlz8yl_bC5ERcdJm9mu_MLSTyl3e_✅ Coaching on Demand (Same day Appointments Available): https://myamazonguy.com/book-a-coaching-call/#amazonselling #amazonseller #amazonfba #myamazonguy

Drs Dekker and Millett discuss The "Bony Bankart Bridge" Procedure: A New Arthroscopic Technique for Reduction and Internal Fixation of a Bony Bankart Lesion

Isa Chandra Moskowitz is a Brooklyn native who began her vegan cooking journey over 20 years ago. She's inspired by New York City's cuisine from all over the world, as well as her own Jewish heritage, and loves to fuse the two together.She is the creator of the Post Punk Kitchen the website (theppk.com) and also the public access television show Post Punk Kitchen. She's been at the vegan game for a long time with multiple cookbooks under her belt, including; Vegan with a Vengeance, Vegan Cupcakes Take Over the World,  Veganomicon, Vegan Brunch,  Vegan Cookies Invade Your Cookie Jar, Appetite for Reduction, Vegan Pie in the Sky, Isa Does It, The Superfun Times Vegan Holiday Cookbook, I Can Cook Vegan and the Modern Love Cookzine.Isa has a new book coming in fall of 2022 titled Fake Meat.Is is the owner and executive chef of both Modern Love Omaha and Modern Love Brooklyn restaurants.Isa Chandra Moskowitz: theppk.com IG: @isachandraDustin Harder: veganroadie.com IG: @theveganroadieDavid Rossetti: @drossettiBUY I CAN COOK VEGAN

Guest: Advocate Mzie Yawa who is the Chief Director for Corporate Services at UIF See omnystudio.com/listener for privacy information.

Toni Vernelli, International Head of Communications and Marketing, Veganuary The daughter of a butcher from a small town in Northern Canada, Toni gave up meat in her teens when she learned that we can live and be healthy without it. Now vegan for more than 30 years, she believes passionately that we need a mass shift towards plant-based eating and is proud to be part of an organisation fuelling this change. She also holds a PhD in Animal Behaviour. www.veganuary.com @weareveganuary

The law & politics do not take a break for the holidays, so neither does the LegalAF x MeidasTouch podcast. Anchored by MT founder and civil rights lawyer, Ben Meiselas and national trial lawyer and strategist, Michael Popok, the top-rated news analysis podcast is back for another hard-hitting, thought-provoking look in “real time” at this week's developments.  On this first episode of 2022, Ben and Popok analyze: 1. Ghislaine Maxwell Sentencing and Broader Implications. 2. Colorado Governor Commutation of the Sentence Down to 10 Years for Truck Driver sentenced to 110 years for reckless homicide in highway pileup that killed 4 people. 3. 5th Circuit Taking Up Texas Abortion Ban Law—Again. 4.Oklahoma's Efforts to Prevent National Guard from being Vaccinated is Rejected. 5. The NY Times and its appellate efforts against a trial judge's order preventing reporting on Project Veritas as an unconstitutional violation of its First Amendment rights (i.e. “prior restraint”). 6.The Biden Administration ramping up of antitrust and other anticompetitive laws and directives in the shipping, meat, and fuel industries to address the highest inflation in 40 years. 7. Jan6 Committee Updates including the National Archive case before SCOTUS, & Minority Leader McCarthy receiving an “invite” to appear. And much more. Support the Show! AG1 by Athletic Greens -- Athletic Greens is going to give you an immune supporting FREE 1 year supply of Vitamin D AND 5 free travel packs with your first purchase if you visit https://athleticgreens.com/legalaf today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Erin Scala explores the wines of Pico Island, a part of the Portuguese Azores in the Atlantic Ocean.This episode also features commentary from (in order of appearance):Vanda Supa, Director of Environment and Climate Change of PicoMonica Silva Goulart, Architectural Expert of the Pico Island VineyardsPaulo Machado, Insula and Azores Wine CompanyDr. Joy Ting, Enologist at the Winemaker's Research ExchangeAntónio Maçanita, Azores Wine CompanyCatia Laranjo, EtnomAndré Ribeiro and Ricardo Pinto, Entre PedrasLucas Lopez Amaral (translated by Paulo Machado), Adega Vitivinícola Lucas AmaralTito Silva (translated by Fortunato Garcia), Cerca dos FradesJose Eduardo and Luisa Terra, Pocinho BayFortunato Garcia, Czar WineryBernardo Cabral, Picowines Co-opFilipe Rocha, Azores Wine CompanyChristina Cunha (for her uncle Leonardo da Silva), Santo Antonio CarcaritaMarco Faria, Curral Atlantis WinerySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A new report says the University of Minnesota Twin Cities campus has surpassed its goal of cutting greenhouse gas emissions in half by 2021. It reached 51 percent a year early, in 2020.

The Government is considering a reduction in the €3,000 student contribution charge as part of a new funding package for the third level sector due to be published next month. With reaction to this, we spoke to the President of the Union Students of Ireland, Clare Austick.  Listen and subscribe to Newstalk Breakfast on Apple Podcasts or Spotify.     Download, listen and subscribe on the Newstalk App.    You can also listen to Newstalk live on newstalk.com or on Alexa, by adding the Newstalk skill and asking: 'Alexa, play Newstalk'.

Fatima “Fatti” Tarkleman is a zero-waste, British migrant chef of mixed African-Asian descent. She has special interests in cross-cultural cooking that prioritises sustainability, inclusivity, and local produce, while representing her London upbringing and the flavours of her heritage. Fatima works as a private chef, workshop facilitator, recipe writer, and content creator. She embraces innovative ways of using age-old techniques to make delicious food, putting care for people, their stories, and nature at the heart of her practice. @foodventures_with_fatti

Racquel Garcia and Ali Hall discuss Motivational Interviewing as part of recovery coaching with host Jeff Olivet. Visit c4innovates.com, subscribe to receive newsletter and training updates, and follow us on Twitter, Facebook, LinkedIn, and YouTube for more resources to grow your impact. Learn More Racquel Garcia: HardBeauty, HardBeauty Foundation Ali Hall: MINT profile, website Motivational Interviewing: training opportunities and resources from C4 Innovations More podcast episodes on Motivational Interviewing Motivational Interviewing: resources from the Motivational Interviewing Network of Trainers (MINT) Access a transcript of Motivational Interviewing 16: Racquel Garcia (coming soon)

We started off this week's show by chatting with Tom Jahnke, President of Builder Supply Outlet about making 15 custom interior doors for a listener before the holidays. Next, Senior Restoration Manager of J.C. Restoration, Cory Ambrose, joined the show to talk about their new merger with BluSky. Then, VP of Sales at Access Elevator, […]

TSN Hockey Insider Chris Johnston joined Julia Tocheri and Al's Brother joined Leafs Lunch to react on Paul Maurice's surprise resignation, discuss how everything is on the table in the NHLs respond to the recent COVID uptick, the latest on Jason Spezza's suspension being reduced from six to four games, the Canucks turn-around under Bruce Boudreau and what his biggest surprise has been through the first quarter of this NHL season.

Today I speak to Founder of Cultivating Minds UK, leadership and violence prevention trainer, former Chief Inspector in the Scottish Police force and member of the Scottish Violence Reduction Unit - Graham Goulden. With recent well publicised cases of violence against women in the news and also cases of violence being perpetrated by members of police forces on both sides of the Atlantic, right now it's never been such a topical subject. How as a society we being to challenge the behaviour of individuals within our institutions, organisations and even peer groups in the future is a challenge that needs to be taken up. Graham and I discuss: How the cases of Sarah Everard and George Floyd have really case a light on police forces but also how organisations allow attitudes to take hold. The importance of men being reflective about their own behaviour and their behaviour in the past How all men can set an example, be a role model and set the tone for masculinity. Why building character in young men is so important and the strength of building a personal brand for young men to live by. The destructive influence of imaginary peers in how boys shape their behaviour towards girls.

The digitization of health records coupled with the increasing capability of Natural Language Processing has made autonomous coding possible. The main benefit of this technology is not the potential cost reductions, but rather the potential improvement in revenue that it brings.Neal Somaney, Co-Founder of Medical Savant and EVP at CorroHealth sat down with us to educate us on this new technology. Learn more about CorroHealth: https://corrohealth.com/ Find more great health IT content: https://www.healthcareittoday.com/

In light of the multiple potato wart finds on Canada's Prince Edward Island (PEI), during a meeting of the Potato Association of America on December 1, 2021, the Canadian Food Inspection Agency (CFIA) provided growers and industry partners an update on its soil sampling efforts throughout the province's potato production area. Kam Quarles, CEO of the National Potato Council calls in to discuss how CFIA's own data -- which demonstrates a clear and troubling reduction in sampling -- leaves the industries on both sides of the border with uncertainties about the spread of the disease on PEI and what the future holds for reopening trade with this important industry partner. 

Jim and Jeff talk with John Tolbert, Lead Analyst and Managing Director at KuppingerCole, to learn more about fraud reduction intelligence platforms and how they fit into an identity program's capabilities. Connect with John on LinkedIn: https://www.linkedin.com/in/john-tolbert/ Learn more about KuppingerCole: https://www.kuppingercole.com/ Fraud Reduction Intelligence Platform Leadership Quadrant: https://plus.kuppingercole.com/article/lc80488/fraud-reduction-intelligence-platforms/ Connect with Jim and Jeff on LinkedIn here: Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/ Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/ Visit the show at www.IdentityAtTheCenter.com, follow @IDACPodcast on Twitter, and check out our live streams at www.idac.live --- Send in a voice message: https://anchor.fm/identity-at-the-center/message

Earth911 talks with Lisa Ryden, Sustainable Development Director at Tetra Pak, the world's largest carton manufacturer about its 2021 corporate sustainability report and the steps the company is taking to reduce its environmental impact. Tetra Pak has established itself globally, selling 183 billion cartons in 2020. The brand name has become synonymous with cartons in many regions, where they are referred to as a “Tetra.” Lisa shares the company's 2030 goals and explains some of the challenges of reducing its carbon emissions by 46% compared to 2019 and achieve net-zero Scope 1 and 2 emissions by the end of the decade. In the past year, Tetra Pak has launched a plant-based carton made with renewable materials, shipped 12 billion caps made from plant-based materials, and they replaced the aluminum liner used in early generations of cartons with a polymer that has a 25% lower carbon footprint. Tetra Pak's CO2 emissions peaked in 2010 and it has reduced the volume of food waste in its manufacturing processes by 50% over the past decade.Cartons represent an emerging alternative to plastic packaging for beverages and food. The only beverage category that fiber cartons cannot serve are carbonated drinks, and more food manufacturers are considering cartons for, among other things, cheese -- Tetra Pak recently introduced a cheese packaging solution. Tetra Pak has more than 170 recycling processor partners globally. The company reports that 27% of the cartons it made in 2020 were recycled and has set a goal of reaching 70% recycling rates in Europe by 2030. Cartons remain a recycling challenge in the U.S., where there are only three carton recycling processing facilities -- this makes recycling cartons less sustainable because they must be shipped a thousand miles in many cases to be processed. You can learn more at https://tetrapak.com.

Ellen Tout is a sustainability writer passionate about helping us reduce food waste. After writing about sustainability for many years, she became fascinated by compleating – eating all edible parts of fruits, vegetables and herbs. Ellen's debut book, The Complete Book of Vegan Compleating, is out now and shows us how to make the most of our ingredients, save money, have fun with food and reduce food waste by compleating. For more, see ellentout.com @ellen_tout @compleatly_vegan

Please join Guest Host Mercedes Carnethon along with first author Connie Hess and Guest Editor Gregory Lip as they discuss the article "Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Poly Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, our feature discussion is on a really important topic, peripheral artery disease. So important, so rampant, not talked about enough. And it's really insights from the VOYAGER-PAD trial telling us about the reduction in acute limb ischemia with Rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization. But before we get into all that, I want you to get your coffee while I tell you about my picks of today's issue. Should I start? Dr. Greg Hundley: Very good. Dr. Carolyn Lam: Okay. So the first paper deals with the residual ischemic risk following coronary artery bypass grafting surgery. We know that despite advances, patients following CABG still have significant risk. So this paper refers to a subgroup of patients from the REDUCE-IT trial with a history of CABG, which was analyzed to evaluate the efficacy of icosapent ethyl treatment in the reduction of cardiovascular events in this high risk patient population. Now, as a reminder, the REDUCE-IT trial was a multicenter, placebo controlled, double blind trial, where statin treated patients with controlled LDL cholesterol and mild to moderate hypertriglyceridemia were randomized to four grams daily of icosapent ethyl or placebo. They experienced a 25% reduction in risk of a primary efficacy endpoint, which was cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina. Now the current report tells us about the subgroup of patients from the trial with a history of CABG. Dr. Greg Hundley: Ah, Carolyn. So what did they find in this subgroup of patients? Dr. Carolyn Lam: So of the 8,179 patients randomized in REDUCE-IT, 22.5% had a history of CABG with 897 patients randomized to icosapent ethyl and 940 to placebo. Baseline characteristics were similar between the treatment groups and randomization to icosapent ethyl was associated with a significant reduction in the primary endpoint, as well as in key secondary endpoint and in total ischemic events compared to placebo. This yielded an absolute risk reduction of 6.2% in first events with a number needed to treat of 16 over a median follow up time of 4.8 years. So, Greg, I think you'll agree, icosapent ethyl may be an important pharmaco-therapeutic option to consider in eligible patients with a history of coronary artery bypass grafting surgery. Dr. Greg Hundley: Very nice, Carolyn. What an excellent summary. So Carolyn, for my first paper... And this study comes to us from Professor Judith Haendeler from the Leibniz Research Institute for Environmental Medicine. So Carolyn, this is a new type of quiz question. And as you listen to the presentation, help us predict the clinical implications. Okay, here we go. Dr. Greg Hundley: All right. So Carolyn, telomerase, also called terminal transferase, is a ribonuclear protein that adds a species dependent telomere repeat sequence to the three prime end of telomeres. And Carolyn, just to refresh our memories, a telomere is a region of repetitive sequences at each end of the chromosomes of most eukaryotes. And telomerase was discovered interestingly by Carol Greider and Elizabeth Blackburn in 1984. And together with some others, including Jack Szostak, they were awarded the 2009 Nobel Prize in physiology and medicine for discovery. Dr. Greg Hundley: So Carolyn, telomerase is active in gamuts and most cancer cells, but is normally absent from or at very low levels in most somatic cells. And the catalytic subunit of telomerase called telomerase reverse transcriptase or trt has protective functions in the cardiovascular system, particularly in regard to ischemia reperfusion injury. And interestingly trt or telomerase reverse transcriptase is not present in the nucleus, but also in mitochondria. However, for us in cardiovascular medicine, it is unclear whether nuclear or mitochondrial trt is responsible for the observed protection. Dr. Carolyn Lam: Wow, fascinating. So what did today's paper find? Dr. Greg Hundley: Right, Carolyn. So it was mitochondrial, but not nuclear telomerase reverse transcriptase that was found critical for mitochondrial respiration during ischemia reperfusion injury. And mitochondrial telomerase reverse transcriptase improves complex 1 subunit composition. And trt is present in human heart mitochondria and remote ischemic preconditioning increases its level in these organelles. Also, Carolyn TA65 was found to have comparable effects ex vivo and improved migratory capacity of endothelial cells and myofibroblast differentiation. So Carolyn, with this summary, can you help speculate on the clinical implications of this paper? Dr. Carolyn Lam: Oh, Greg. You set it up so nicely. So I would speculate that the clinical implications are that an increase in the mitochondrial telomerase reverse transcriptase or trt would be able to help with cardioprotection in ischaemic reperfusion injury, or at least that's what we hope and that's where we should be going with this. Am I right? Dr. Greg Hundley: Absolutely, Carolyn. So in the future, this research showing that trt and cardioprotection... Maybe we increase this and it could serve as a therapeutic strategy. Excellent job, Carolyn. Dr. Carolyn Lam: Thank you, Greg. All right. My next paper is a preclinical paper. I will spare you of difficult quizzes and maybe... This is just so neat. Let me tell you about it. So the study really provides novel insights into the mechanisms underlying smooth muscle cell phenotypic modulation that contributes to the development of vascular diseases like renal atherosclerosis and restenosis after angioplasty. So very important. Dr. Jiliang Zhou from Medical College of Georgia and colleagues basically used an in silico approach to probe unbiased, proprietary, and diverse, publicly available bulk RNA-Seq and scRNA-Seq datasets to search for smooth muscle cell specific long non-coding RNAs or lncRNAs. Dr. Carolyn Lam: The search ended up identifying CARMN, which stands for cardiac mesoderm enhancer-associated non-coding RNA, CARMN. As a highly abundant, highly conserved smooth muscle cell specific lncRNA, CARMN was recently reported to play roles in cardiac differentiation and was initially annotated as a host lncRNA for the microRNA, the MIR143145 cluster, which is the best characterized microRNAs in regulating smooth muscle cell differentiation and phenotypical modulation. Dr. Carolyn Lam: But in the current study, the authors confirmed the expression specificity of CARMN using a novel GFP knock-in reporter mouse model, and discovered that CARMN is downregulated in various vascular diseases. They further found that CARMN is critical for maintaining vascular smooth muscle cell contractile phenotype, both in vitro and in vivo by directly binding to the smooth muscle cell specific transcriptional cofactor known as myocardit. Dr. Greg Hundley: Okay. Carolyn, what a beautiful summary here. So what's the take home message here? Dr. Carolyn Lam: So these findings collectively suggest that CARMN is a key regulator of vascular smooth muscle cell phenotype, and therefore represents a potential therapeutic target for the treatment of smooth muscle cell related proliferative diseases. Dr. Carolyn Lam: Well, Greg, thanks for letting me to tell you about that one. But let me tell you also about other papers in today's issue. There's an exchange of letters between Dr's Lee and Chew on high rates of coronary events in the rapid troponin T0 one hour protocol. Is it a reality or illusion? There's an ECG Challenge by Dr. Liu on “Acute Inferior Wall Myocardial Infarction. What is the Culprit Artery? In Cardiology News, Bridget Kuehn writes on persistent heart effects of COVID-19 and how that emphasizes the need for prevention. Dr. Greg Hundley: Very nice, Carolyn. Well, I've got a Research Letter to tell you about from Professor Huang, entitled “High Prevalence of Unrecognized Congenital Heart Disease in School-Age Children in Rural China: A Population-Based Echocardiographic Screening Study.” Well, Carolyn, what a fantastic issue. And how about we get onto that feature discussion now and learn more out lower extremity revascularization and insights from the VOYAGER-PAD study? Dr. Carolyn Lam: Let's go, Greg. Dr. Mercedes Carnethon: Good morning, everyone. Welcome to this episode of Circulation on the Run podcast. I'm Mercedes Carnethon, Professor and Vice Chair of Preventive Medicine at the Northwestern University Feinberg School of Medicine and associate editor of the journal. Really excited today to hear from one of our authors of a particularly interesting piece that we'd like to discuss today about peripheral artery disease after lower extremity revascularization. Dr. Mercedes Carnethon: And we have with us today, the lead author, Dr. Connie Hess from the division of cardiology at the University of Colorado School of Medicine in Aurora. And we have Dr. Gregory Lip with us. So welcome to the both of you. Professor Gregory Lip: Hello there. Dr. Connie Hess: Thank you for having me. Dr. Mercedes Carnethon: Thank you both for joining us. This is really exciting. I know that when I read this piece, I was really excited to think about the implications that these study findings from this clinical trial will have for a very important clinical problem of peripheral arterial disease and those complications. So, Connie, would you be willing to start by telling us a little bit about what you found in this study? Dr. Connie Hess: Yeah, absolutely. I think maybe a good place to start first is, if that's okay, is just a little bit of the background and why we looked at this and thought to look at this. I think as you're both probably aware, peripheral artery disease is a very highly prevalent condition. It affects a lot of people, but there's not a lot of awareness about it. It's in some ways the forgotten manifestation of atherosclerosis. And so acute limb ischemia in particular is a very feared complication of peripheral artery disease. And unlike things like ST elevation, myocardial infarction, and stroke about which patients and providers have a lot of knowledge and understanding, many people don't know about acute limb ischemia. And in particular ALI, acute limb ischemia, is a complication of peripheral revascularization that many of us as proceduralists are very concerned about. Dr. Connie Hess: And so what we wanted to do was use this very unique clinical trial and dataset to look at acute limb ischemia, to describe it, to better understand it, especially after a peripheral revascularization. And then also to look at the effect of Rivaroxaban plus aspirin versus aspirin alone on this feared outcome. We're lacking therapies to effectively prevent ALI. Dr. Connie Hess: And so if I just briefly review the trial, VOYAGER-PAD randomized 6,564 patients undergoing peripheral revascularization, both surgical or endovascular to Rivaroxaban, 2.5 milligrams twice daily versus placebo on top of aspirin. And then providers could use prochidagril for up to six months per their discretion. Now, the primary outcome for VOYAGER-PAD was very unique. This was a five point composite that looked at acute limb ischemia, major amputation of vascular etiology, myocardial infarction, ischemic stroke, or cardiovascular death. Dr. Connie Hess: And so in this trial in the primary results, Rivaroxaban plus aspirin versus aspirin alone was highly effective in reducing the primary endpoint, that five point composite I just described. And so we were excited to look specifically at the effect of this combination therapy on acute limb ischemia alone. What we found to begin with, I think in terms of describing acute limb ischemia is important. So the three year cumulative incidence in the patients assigned a placebo was about 8% for ALI. So this is not an uncommon problem. And in fact, we found that there was incidents of ALI occurring quite early after the procedure and that the risk persisted, even three years out. Dr. Connie Hess: And Rivaroxaban plus aspirin versus aspirin alone was very effective in reducing ALI by about 33%. Beyond that, we also looked at ALI in terms of severity of these complications. And we found that about a third of patients had a very severe ALI event that we defined as ALI followed by death, major amputation, or requiring a prolonged hospitalization with time in the intensive care unit. And for those patients, Rivaroxaban plus aspirin was even more effective with almost a 55% reduction. Dr. Connie Hess: Lastly, I think we also looked at just the patients who are at risk for ALI after peripheral revascularization. And we did identify some patient and procedural factors that might help us identify these patients. For example, having a prior lower extremity revascularization, having more severe PAD as indicated by a low ankle brachial index, undergoing surgical revascularization, and having longer target lesions. So I think we were able to describe ALI in a way that some other trials and datasets have not been able to do. And then also beyond that to provide some evidence for effective therapy to prevent this complication. Dr. Mercedes Carnethon: All of that is so exciting. And for somebody coming to this outside of the initial field, I can certainly see a lot of innovations that you describe in what you've done and the importance to the population of people who experience this very debilitating illness. So it's really wonderful to see this in print. So tell me, Greg, what excited you as the editor about this particular paper? So what made it really stand out in your mind? Professor Gregory Lip: Thanks, Mercedes. And firstly, congratulations to Dr. Hess for a really nice paper. And I think that it's really important because many cardiologists tend to neglect looking at and managing peripheral artery disease, especially with the medical therapies. And I think VOYAGER-PAD was an important advancement of how we can have... You could say, dual blockade, both with low dose anticoagulation plus antiplatelets should improve the outcomes. Professor Gregory Lip: So I think it really brings to the forefront how we should optimize medical therapy and peripheral disease. It's not simply a matter of surgery or just intervention with stenting. And I think maybe the other important aspects in regard to this study, this trial is when you combine an antiplatelet with an anticoagulant, it's worth flagging up the potential for added risk of bleeding. And it's therefore the fact that your analysis included to identify the patients at high risk of acute limb ischemia, then we will actually facilitate risk stratification so that we can perhaps target the very high risk patients where that balance in terms of the net benefit for the combination therapy compared to aspirin alone would be there because you're balancing the thrombotic and limb ischemic outcome versus the potential for bleeding. Professor Gregory Lip: We are also using of course, in VOYAGER-PAD low dose Rivaroxaban, which is not the stroke prevention dose of Rivaroxaban in everyday clinical practice. And that's worth emphasizing. So we translate peripheral disease dosages or regimes versus what we see in other prothrombotic situations like atrial fibrillation, which leads to stroke. And that's probably worth emphasizing. And I think really what is most important is that we can hopefully identify the high risk subset of patients with peripheral artery disease at risk of acute limb ischemia, where they're going to particularly benefit from combination therapy. So an important advance for medical therapy for peripheral disease. So congratulations on this paper as well. Dr. Mercedes Carnethon: Yeah. I really echo that. One of the things that when we write original research papers, we are always encouraged not to speculate beyond the data that we're presenting. But one of the values of this podcast is that we get a chance to really needle the authors and challenge them to speculate about what does this mean? What does this mean for the field? And Connie in particular, what do you think the next steps are for patients and providers based on what you found today in this excellent study? Dr. Connie Hess: Mercedes, that's a great question. Certainly we always want to know what next? What are the implications of these findings? And so to me, I echo both of you. I'm personally very excited as someone in the field. And as a proceduralist, I'm very excited that for the first time, we actually have data to support a medical therapy post intervention. Although there's a lot of use of things like dual antiplatelet therapy and even anticoagulation, there's not a lot of data to support it after peripheral revascularization. So this really is the first large scale, high quality data to support a strategy. And so I do think that this is something that we should adopt. Dr. Connie Hess: I think what I didn't mention before is that actually, when you look at the cumulative incidence curves for ALI in the Rivaroxaban versus placebo groups, not only do you see that there is early risk for ALI after the procedure... And typically we think of this as potentially technical failure that we can't modify, but you saw a very early benefit for Rivaroxaban plus aspirin versus aspirin alone here, suggesting that the sooner you start, the better. Of course, it has to be when it's safe from a bleeding perspective and when the proceduralist feels comfortable with this. But I do think that the implications are that we should... We proceduralists, especially in this population and as professor Lip mentioned the high risk patients in particular, should be starting this therapy as soon as we feel safe. And so I think the data are there. The next step to me is really increasing awareness, in particular among providers who are treating these patients, but even among our other colleagues or cardiovascular colleagues who may not treat these peripheral artery disease patients primarily, but do see them in their clinic. Dr. Connie Hess: A lot of them have cardiovascular disease and other cardiovascular problems, but to increase awareness that this dual pathway inhibition with low dose factor 10, anticoagulation inhibition and low antiplatelet therapy is a viable and favorable combination and to continue this so that when they see this, they're not surprised and not questioning whether to stop it. Dr. Connie Hess: I think also of course now that we are getting more data to understand how morbid and bad ALI is, I do think we also need to educate patients. You both probably recall all the tremendous efforts that were made to increase awareness in the patient population about myocardial infarction and stroke. You have all those campaigns and understanding the importance of timely intervention and reperfusion. I think that actually should be done for acute limb ischemia as well. We need to have providers aware about this complication and understanding emergent treatment. We also need patients to understand it so they can come in sooner so that they're not having delayed presentation for which primary amputation is the only treatment option. So I think there's a lot of work to be done, but certainly very excited that we have a better understanding of ALI as well as preventive therapy. Dr. Mercedes Carnethon: I really appreciate that final word. And I really can't think of a better way to wrap up than the final words that you provided, Connie. Both the context that you provided around this piece and your thoughts as well, Greg, about what makes it innovative and exciting for our readership at Circulation are really invaluable. So I just really want to thank you for joining us as an author and thank you for selecting this, Greg. This is a really great piece. I've learned a good deal. Dr. Mercedes Carnethon: This is me, Mercedes Carnethon, wrapping up this addition of Circulation on the Run, following an outstanding discussion with Dr. Connie Hess from the University of Colorado and Greg Lip, the handling editor for the piece. Dr. Greg Hundley: This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit ahajournals.org.

Climate experts are hailing Labor's election promise to make a 43 per cent emissions cut by 2030 as a step in the right direction, but warn it is a goal that falls short of what the science calls for. To limit global warning within the Paris Agreement goal of "well below" two degrees, scientists and Greens activists are pushing for a 75 per cent emissions cut. - Експертите за клима го поздравуваат изборното ветување на Лабуристичката Партија за намалување на емисиите за 43 отсто до 2030 година, како чекор во вистинската насока, но предупредуваат дека тоа е цел што е под она што науката го бара. За да се ограничи глобалното затоплување во рамките на целта на Парискиот Договор за „многу под“ два степени, научниците и активистите на Зелените се залагаат за намалување на емисиите за 75 отсто.

Shadow Climate Change Minister Chris Bowen has flatly ruled out any deals with the Greens to pass a 43% carbon target, if Labor wins the election and has to deal with a hung Parliament. If an Albanese Government can't legislate the target - it will introduce it by other means.

Even when you lose weight, the cellulite hangs around, doesn't it? And it looks lumpy, wrinkly, and dimpled! But there is a solution! Call Cellulite Physician Services (816-569-1690) today to book a free consultation. You can check them out at https://cellulitephysicianservices.com/indiba (https://cellulitephysicianservices.com/indiba)

Scientists and Greens activists are pushing for a 75 per cent emissions cut.

https://www.statnews.com/2021/11/04/what-moderna-owes-the-world/ https://www.propublica.org/article/heres-why-rapid-covid-tests-are-so-expensive-and-hard-to-find https://lexfridman.com/michael-mina-2/ https://www.cnbc.com/2021/11/03/cdc-director-urges-kids-whove-had-a-prior-covid-infection-to-still-get-vaccinated.html https://jackmcintire.substack.com/p/i-went-back-to-harvard-and-got-mad https://www.pewresearch.org/politics/2021/11/09/beyond-red-vs-blue-the-political-typology-2/ https://www.npr.org/2020/12/15/945031391/poll-despite-record-turnout-80-million-americans-didnt-vote-heres-why https://www.nytimes.com/2021/11/02/opinion/constitution-slavery-lincoln.html Housing Discrimination: Last Week Tonight with John Oliver (HBO) https://www.youtube.com/watch?v=_-0J49_9lwc https://www.kurzweilai.net/book-the-social-singularity https://www.jimruttshow.com/max-borders/ https://www.jimruttshow.com/max-borders-2/ https://www.jimruttshow.com/max-borders-3/ https://lexfridman.com/max-tegmark/ https://lexfridman.com/max-tegmark-2/ https://www.jimruttshow.com/ben-goertzel/ https://www.jimruttshow.com/currents-ben-goertzel/ https://integralcity.com/about/vision-mission-and-values/ Carl Sagan's insightful book about science as a candle in the dark: https://en.wikipedia.org/wiki/The_Demon-Haunted_World upcoming freedom conference... The Greater Reset 3: Integration Jan 26-30, 2022 - In-Person Events in Austin, TX and Morelia, Mexico https://thegreaterreset.org Bill Kristol and Scott Horton Debate U.S. Interventionism https://www.youtube.com/watch?v=LxdXqAkgOVs Making Monsters: The Uncanny Power of Dehumanization by David Livingstone Smith https://www.amazon.com/Making-Monsters-Uncanny-Power-Dehumanization/dp/0674545567/ https://www.warwicks.com/event/smith-2021 https://lexfridman.com/richard-wrangham/ https://buyenov.com Nasal Spray for Virus/SARS-COV-2 Reduction https://www.youtube.com/watch?v=u-e_XYYHApA https://odysee.com/@DrMobeenSyed:1/nasal-spray-for-virus-sars-cov-2:1 bumper music Rachmaninoff - Rhapsody on a Theme of Paganini, Op. 43 https://www.youtube.com/watch?v=HvKTPDg0IW0

Jim Salisbury and Corey Seidman discuss:0:00 - Key points of the lockout7:15 - Reduction of MLB salaries9:30 - Corey Knebel signing16:30 - Bigger market for Kyle Schwarber23:06 - What about Freddie Freeman?25:30 - Chances Dick Allen makes the Hall of Fame?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The federal opposition says cutting emissions by 43 per cent by 2030 would create more than 600,000 jobs and see renewables account for 82 per cent of the National Electricity Market by 2030.

The number of people legally allowed to enter the Boundary Waters Canoe Area Wilderness (BWCA) for overnight camping trips from May through September will be reduced for the next paddling season. With permits in high demand during recent paddling seasons – particularly during the past two seasons amid the ongoing COVID-19 pandemic – some canoeists struggled to find available campsites, particularly near popular lakes such as Sawbill, Brule, Duncan and Seagull on the east side of the BWCA. Anecdotally speaking, weary paddlers are quick to complain about racing other groups for campsites, being forced to camp illegally in the brush or making camp in the middle of a pleasant travel day just to ensure they have a site for the night. Each year from May 1 to Sept. 30, visitors taking an overnight paddle or hiking trip, or a motorized day trip into the BWCA are required to obtain a quota permit. The Forest Service designed a quota system following the designation of the Boundary Waters as a wilderness to reduce crowding and visitor impacts on sensitive resources. Forest Service officials said many BWCA entry points and associated routes are regularly experiencing social resource concerns such as crowding, disruptive and oversized groups, lack of campsite availability or unsettling competition for campsites. Illegal camping is also becoming more of a problem in the BWCA. Ten out of the 36 entry points on the Gunflint and six of the 13 entry points on the Tofte districts will see a reduction in permit quota numbers in 2022. The Forest Service declined to say the specific entry points the quota reduction will impact. All districts across the BWCA will see a quota reduction next year other than the Kawishiwi Ranger District.

We explore how overweight and obesity are linked with persistent pain and the importance of physical therapists promoting combined nutrition, exercise, and weight loss programs when treating chronic pain syndrome. Joining us as an expert guest is Anneleen Malfliet. She is an Assistant Professor, Postdoctoral Researcher, and a member of the Pain in Motion international research group. Research in clinical investigations centers on chronic pain with a special interest in spinal pain, central sensitization nutrition, and diet. In this episode, we will explore the broader lifestyle perspective when considering the link between obesity and chronic pain, how a clinician can assess the presence of obesity or be overweight. Finally, how to approach weight reduction and organize a weight management program in clinical practice. There is a lot packed into this episode. You will gain a lot from the information and data that Anneleen has around the impact of obesity on chronic pain. Let's begin and meet Anneleen Malfliet.   Love the show? Subscribe, rate, review, and share! Here's How » Join the Healing Pain Podcast Community today: integrativepainscienceinstitute.com Healing Pain Podcast Facebook Healing Pain Podcast Twitter Healing Pain Podcast YouTube Healing Pain Podcast LinkedIn Healing Pain Podcast Instagram

Steve and Frank are back with the latest cloud FinOps news for September! This episode covers the following topics: Amazon Redshift extends Automatic Table Optimization to support Column Compression EncodingAWS Cost Categories introduces Split Charge rules for allocation of shared costsAmazon MSK adds metrics for increased visibility of capacityAmazon Textract Updates: Up to 32% Price Reduction in 8 AWS Regions and Up to 50% Reduction in Asynchronous Job Processing TimesAmazon Elastic File System introduces Intelligent-Tiering to automatically optimize storage costsAmazon S3 Intelligent-Tiering – Improved Cost Optimizations for Short-Lived and Small ObjectsGeneral availability: Azure Files supports storage capacity reservations for premium, hot, and cool tiersPublic preview: Scale-down mode in AKSGeneral availability: Lower capacity reservation tier for Azure Monitor dedicated clusters AWS CodeBuild now supports a small ARM machine type Amazon RDS now supports T4g instances for MySQL, MariaDB, and PostgreSQL databasesNow auto-terminate idle EMR clusters to lower costVisit our website to find out more about cloud FinOps.

Today, Dom Giordano leads off black Friday by asking listeners for what they believe to be the best bargains of all time. Then, Giordano moves into a discussion of crime, highlighting a Tweet by Fox29's Steve Keeley, calling attention to the Dallas crime and homicide rate. Dallas, a city of comparable size to Philadelphia, has seen crime decrease while we in Philadelphia have seen record-setting crime numbers. Giordano and producer Dan discuss the underlying reasons for this, and ask how the Mayor and DA can argue that the pandemic and guns are at fault for the rash of violence, while a state that has less strict gun and COVID laws have seen a decrease. Then, Alan Dershowitz rejoins the Dom Giordano Program to discuss the result of the Ahmaud Arbery case, in which all three assailants were determined guilty of felony murder and multiple other counts. First, Dershowitz tells of when he was scolded in Martha's Vineyard by Larry David, telling his regret of falling out of a relationship with somebody he used to consider a close friend. Then, Dershowitz gives his thoughts on the trial, and discusses the concept of cancel culture and the changing rhetoric of political discussion. (Photo by Getty Images) See omnystudio.com/listener for privacy information.

It's all too easy to take antibiotics for granted, but if we are not careful it may be that they become next to useless... On today's episode of the Call The Vet podcast, I talk about one of the most serious problems that we may face in the near future, resistance to antibiotics. Antimicrobial resistance is an issue for both humans and animals as we're educating bacteria to adapt themselves to overcome antibiotics, which may mean that simple infections that we used to treat with penicillin or other common antibiotics could once again become deadly.I would like to encourage you to be wary of overusing antibiotics for your animals, as there are ways that we can treat pets with first-class, evidence-based care that avoid unnecessary antibiotics. Today in my own practice, I have become much more cautious of prescribing antibiotics and try to use other approaches first before reaching for antibiotics.Listen in to some of my listener questions about antibiotics, such as if one kind of antibiotic is better than another, what else pet owners should do when their animal is prescribed antibiotics, whether transdermal antibiotic options are available, and more.Please share this episode with anyone who you think would benefit from this important message on appropriate antibiotic usage.Timestamps:[02:47] The overuse of antibiotics: One of the biggest risks to our health and that of our animals[03:25] The history of antibiotics[04:48] Using the right antibiotic for the right infection[05:58] A best guess attempt at prescribing antibiotics[06:43] Why we don't always run tests to find out what the infection is[07:19] What's an inappropriate use of antibiotics?[08:20] The most common inappropriate usages of antibiotics in dogs[09:56] Inappropriate antibiotic usage in cats[11:47] Reduction in the use of antibiotics[13:13] Talking to pet owners about antibiotic usage[14:29] Are there any kinds of antibiotics that are better or safer than others?[16:59] Should cats take probiotics at the same time as antibiotics?[18:01] What else should a pet owner do when their animal is taking antibiotics?[19:16] Are there transdermal antibiotic options available?[20:49] Other methods of administering medication to animals[23:15] We're all part of the solution Head over to the full show notes for more information on safe, responsible antibiotic use in pets

The global marine shipping and aviation industries are each responsible for about 3% of greenhouse gas emissions.  These are relatively small numbers, but as other industries decarbonize, the contributions from shipping and aviation will loom larger and larger. In October, both of these industries made commitments to reach net zero emissions by 2050.  How can […]

The last episode of this two-part series covered why readmissions occur. This episode explores those causes in more depth – the clinical and social issues underneath readmissions—and what health care organizations can do to prevent these from happening.   Guest speaker: Tod Baker, BS Principal Operations and Quality Vizient   Moderator: Tomas Villanueva, DO, MBA, FACPE, SFHM Principal Clinical Operations and Quality Vizient   Show Notes: [00:40] Addressing clinical issues [02:59] Addressing social issues [04:38] Best practices/new approaches in risk stratification [09:00] Engaging the family or community to manage the patient [10:11] Where to start [12:17] Post-acute care   Links | Resources: To contact Modern Practice: modernpracticepodcast@vizientinc.com Tod Baker's contact email: tod.baker@vizientinc.com Designing and Delivering Whole-Person Transitional Care (AHRQ) Click here Vizient's Clinical Data Base (CDB) and readmissions Click here CMS Hospital Readmissions Reduction Program Click here Amy Boutwell, MD, MPP, presents six videos on Multi-visit Patients (MVPs) and readmissions Click here Contact Dr. Amy Boutwell at: amy@collaborativehealthcarestrategies.com   Subscribe Today! Apple Podcasts Amazon Podcasts Android Google Podcasts Spotify Stitcher RSS Feed

In today's market, houses continue to sell quickly after entering the market. So, if your home isn't selling, the price might be a factor preventing it from receiving offers. And, depending on the circumstances, a price reduction could be the best way to get the client's house to sell. But how do you approach the topic with your client? In today's episode, Jimmy explains how to get a price reduction on your listing. Be transparent and upfront about the situation. Before signing a listing agreement, explain to the client that the price might need to go down. Communicate what you're doing throughout the real estate process, like showings, marketing, and meetings. That way, if a price reduction is needed, you can back it up. If possible, use feedback from showings to reinforce that the price is too high. When pitching a price reduction, go to your client with the facts. Explain: how the competition might've changed, feedback from the showings, and pending actions or situations in the area or the property that might affect their current appraisal.  If you can provide these elements, you have credibility and can show why the price reduction is necessary. How to suggest a price reduction: Just asking a client to reduce their price without backing it up makes you look unprofessional—instead, present information to show why a price reduction is essential. For example, if their house has been on the market for X days, and after X showings, there were X (likely zero) offers. Supplement that with statistics from the National Association of Realtors. For example, homes on the market for 3-4 weeks without an offer are likely 10% overpriced. Describe other factors affecting their position in the market, like closings in the area, trending prices for similar homes, and the trending duration of time houses are on the market. Finally, bring up personal factors that emphasize how a price reduction is the best course of action. The client still pays their mortgage (and thus taxes and interest) and maintenance fees. Put the ball in their court.  Remember, it's their house and their decision if they agree to a price reduction. If they decide not to, that's their prerogative. But after a while, if the house still isn't sold, you can go back to them and use that to renegotiate. After a price reduction, you can relaunch and circle back to people who attended past showings to gauge their interest. Do you have a video or content idea that is perfect for your business? Share it with Jimmy! Connect with Jimmy Burgess on LinkedIn and Facebook and his YouTube channel.  If you like what you heard today, we'd love it if you'd share a rating or review and then subscribe to the podcast and tell others about it as well. You can find The Real Estate Sales Podcast on Apple Podcasts, Google Podcasts, Spotify, Audible, and our website, The Real Estate Sales Podcast. 

Lowering Stress for Optimum Health Part 2: What is Vagal Tone? Dr. Jason Jones Elizabeth City NC, Chiropractor The vagus nerve is simply described as the longest nerve in the body which originates as cranial nerve 10 in the brain. It travels down from the brain to the neck and then passes around important organs throughout the body, including the digestive system, pancreas, liver, spleen, lungs, and heart. The vagus nerve is a key part of your parasympathetic nervous system, which controls the “rest and digest” function, countering the “fight or flight” function of the sympathetic nervous system. The vagus nerve influences many functions in the body, including digestion, breathing, and heart rate, all of which impact your overall health. However, one thing you need to pay special attention to is the “tone” of your vagus nerve. The vagal tone is an internal biological process that determines the activities of the vagus nerve. What is vagal tone? The vagal tone is key to the activity of your parasympathetic nervous system. It is measured by tracking both your heart rate and your breathing rate. When you breathe in, your heart rate speeds up a little, and when you breathe out, your heart rate slows down a little. The bigger the difference between your inhalation and exhalation heart rate, the high your vagal tone. So when you have a higher vagal tone, it means that your body can quickly relax after a period of stress. What is the implication of a high vagal tone? High vagal tone helps to improve many body functions, causing: Lower blood pressure Better blood sugar regulation Improved digestion via increased production of digestive enzymes Reduced risk of stroke and cardiovascular disease Reduced migraines Less anxiety Better mood Higher resilience One of the interesting functions of the vagus nerve is that it reads your gut microbiome and activates a response to control inflammation based on whether it detects pathogens or non-pathogens. This way, your gut microbiome can have an influence on your stress levels, mood, and overall inflammation. What is the implication of low vagal tone? Low vagal tone is found to be associated with depression, cardiovascular conditions and stroke, chronic fatigue syndrome, diabetes, cognitive impairment, and a higher rate of inflammation conditions, including all autoimmune diseases (autoimmune thyroid condition, endometriosis, rheumatoid arthritis, lupus, and more). Much research has shown positive feedback between high vagal tone and good overall health. Hence, the more you increase your vagal tone, the more your mental and physical health will improve. Dr. Mladen Golubic, Medical Director of the Cleveland Clinic, states that “The vagal response reduces stress. It reduces your blood pressure and heart rate. Stimulates digestion, and changes the function of certain parts of the brain, and all those things that happen when we are relaxed.” However, do you know that studies have shown that vagal tone can be passed on from mother to child? If you are depressed or anxious during pregnancy, you tend to have lower vagal activity, and once you give birth, your child has a higher chance of having low vagal activity, and low serotonin and dopamine levels. That's more reason why you should learn how to strengthen your vagal tone naturally. You can consult Dr. Jason at our chiropractic office at Elizabeth City, NC, to learn about natural ways to stimulate and strengthen your vagus nerves. This will help to improve your mental, physical, and overall well-being.          

Today on Colorado Edition, we hear why some Coloradans are returning to the small farming communities they planned to leave behind. And, we learn about a new initiative to increase the hiring rates for formerly incarcerated individuals.

Buying power reduction, or BPR, is how brokerage firms limit the amount of option trading a trader can do based on their account size. Today, Jacob joins Tom and Tony to get explicit about how BPR is calculated and look at ways that paying attention to the BPR of a trade can help us evaluate whether we want to make it.

Buying power reduction, or BPR, is how brokerage firms limit the amount of option trading a trader can do based on their account size. Today, Jacob joins Tom and Tony to get explicit about how BPR is calculated and look at ways that paying attention to the BPR of a trade can help us evaluate whether we want to make it.

Despite its noted absence by global leaders at the COP26 conference in Glasgow, Scotland, China is still aiming to curb emissions and become carbon neutral by 2060 — a decade later than targets set by the United States and European Union. But that’s no easy feat for the world’s second-largest economy and biggest polluter. Marketplace’s Jennifer Pak visits the city of Luoyang in central China to explore the hurdles, opportunities and importance of achieving that goal. Plus: Leisure travel makes a comeback; Senate Democrats reach to cap prescription costs for older Americans; and let the tapering begin.

Despite its noted absence by global leaders at the COP26 conference in Glasgow, Scotland, China is still aiming to curb emissions and become carbon neutral by 2060 — a decade later than targets set by the United States and European Union. But that’s no easy feat for the world’s second-largest economy and biggest polluter. Marketplace’s Jennifer Pak visits the city of Luoyang in central China to explore the hurdles, opportunities and importance of achieving that goal. Plus: Leisure travel makes a comeback; Senate Democrats reach to cap prescription costs for older Americans; and let the tapering begin.

New Insta!https://www.instagram.com/therickshielsgolfshow/NEW YOUTUBE CHANNEL: https://www.youtube.com/rickshielsgolfdailyFollow the brand new Rick Shiels Golf Show Podcast Facebook group!Get in touch: podcast@rickshiels.com►My Links:Facebook ► https://www.facebook.com/RickShielsPGA/Twitter ► https://twitter.com/rickshielspgaInstagram ► https://www.instagram.com/rickshielspga/YouTube ► https://www.youtube.com/user/RickShielsPGAGolf See acast.com/privacy for privacy and opt-out information.